產(chǎn)品信息：
|
- 純度： >95%
- 內(nèi)毒素：<2EU/mg
- 貨號(hào)：BE0146
- Clone: RMP1-14
|
 |
應(yīng)用類(lèi)型：
in vivo blocking of PD-1/PD-L signaling
參考文獻(xiàn)：
1、"Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme" Nat Biotechnol 36(8): 758-764.
2、"The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent" Front Immunol 9: 2100.
3、"Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses" Nat Med. doi : 10.1038/nm.4200.
4、"A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1" Cancer Res 75(18): 3800-3811.
5、"Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies" Cancer Immunol Res 3(6): 689-701.
6、"Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity" Cell 162(6): 1257-1270.
7、"PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity" Cell Host Microbe 17(5): 628-641
8、"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer" Nature 520(7547): 373-377.
9、"TGFbeta Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity" Cancer Res 75(11): 2232-2242.
BioXcell功能性抗體（清除、阻斷、中和）現(xiàn)貨團(tuán)購(gòu)中，>50mg大包裝爆款現(xiàn)貨！歡迎選購(gòu)：https://www.univ-bio.com/sales-once-detail.html?id=1056
